Cedilla Therapeutics is a precision oncology that has discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. The firm's conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/25/21 | $82,600,000 | Series B |
Janus Henderson Investors Logos Capital RA Capital Management Third Rock Ventures Woodline Partners | undisclosed |
